Please ensure Javascript is enabled for purposes of website accessibility

Moderna Reports Positive Results for Coronavirus Vaccine Candidate in Elderly Patients

By Eric Volkman – Updated Aug 26, 2020 at 2:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The levels of antibodies produced by mRNA-1273 were comparable to those seen in younger adults, the company said.

Moderna (MRNA 2.12%) was again in the headlines on Wednesday, following hopeful news about its mRNA-1273 coronavirus vaccine candidate.

The company revealed that in a small, early-stage clinical trial, mRNA-1273 produced what Moderna described as "consistently high levels" of neutralizing antibodies that could provide immunity to the coronavirus. These levels are comparable to those produced by younger adults, according to the company, which made the claims in a presentation to the government's Centers for Disease Control and Prevention.

Coronavirus container receiving swab.

Image source: Getty Images.

The volume of antibodies produced was also higher than those of patients who recovered from COVID-19, the disease triggered by the coronavirus.

Moderna added that the vaccine candidate produced no significant adverse effects on the dosed patients. 

The study consisted of 20 participants, ten of whom were between 56 and 70 years old, and the remainder 71 and older. mRNA-1273 was administered in two 100 microgram doses, 28 days apart.

The results of Moderna's study have not yet been published in a peer-reviewed medical journal.  

Nevertheless, they will likely buttress mRNA-1273's position as a leading vaccine candidate -- if not the leading vaccine candidate -- currently undergoing clinical testing. At the moment, it is currently recruiting patients for a phase 3 clinical trial -- the final stage before it can be submitted for approval by major regulators.

According to the company, it is on pace to meet its goal of drafting 30,000 participants in the trial. As of Aug. 21, it had enrolled over 13,000 individuals.

Investors were highly encouraged by the company's announcement. Shares of Moderna were trading 11% higher in early afternoon trading on Wednesday.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$122.23 (2.12%) $2.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.